An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Paragon 28 Launches Phantom® Metatarsal Shortening System
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) has launched its innovative Phantom® Metatarsal Shortening System, designed for in-line shortening osteotomies of the lesser metatarsals, which treat common foot ailments like metatarsalgia and floating toe. The system features a patent-pending cut guide for enhanced precision. CEO Albert DaCosta emphasized the system's potential to drive growth in the forefoot segment, complementing the company's existing portfolio, including TenoTac™ and HammerTube™. The launch aims to provide a comprehensive solution for surgeons addressing forefoot conditions.
Contributors to the design include renowned surgeons, underscoring the system's innovative approach to improving patient outcomes in foot and ankle orthopedic procedures.
Positive
Launch of the unique Phantom® Metatarsal Shortening System, addressing soft tissue imbalances in current procedures.
Expected to drive growth in the forefoot segment, enhancing the company's portfolio of solutions for foot and ankle pathologies.
Includes a patent-pending cut guide for improved surgical precision.
Negative
None.
ENGLEWOOD, Colo.--(BUSINESS WIRE)--
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of the lesser metatarsals. These osteotomies are preformed to prevent metatarsalgia and floating toe, two of the most frequently addressed foot and ankle pathologies. The system includes a patent pending cut guide allowing for increased precision when performing the correction.
Phantom® Metatarsal Shortening System (Graphic: Business Wire)
Mark Myerson, MD, Phantom® design surgeon, said, "Many implants are re-iterations of existing products, however the Phantom® Metatarsal Shortening System is truly unique, innovative, and quite novel. The ability to precisely and accurately shorten the metatarsal with simple and rigid fixation will be a tremendous addition to the management of various forefoot pathologies".
Paragon 28’s CEO, Albert DaCosta, commented, “We set out to design an implant that addressed the limitations of current procedures, in particular the soft tissue imbalance associated with shortening procedures of the lesser metatarsals. We are thrilled to have accomplished this ambition with the launch of the Phantom® Metatarsal Shortening System and expect this addition to catalyze growth in the forefoot segment of our business. We understand the value that comes from having a comprehensive forefoot portfolio to pair with our bunion offering allowing facilities and surgeons to work with a single partner to meet all their forefoot and bunion needs.”
The Phantom® Metatarsal Shortening System bolsters Paragon 28’s forefoot and bunion solutions offering, which includes the TenoTac™, Paratrooper™, HammerTube™, Gorilla® Precision™ Lapidus Plate, and Phantom® MIS Lapidus Nail. With this comprehensive portfolio, Paragon 28® provides its customers with a single source to address their forefoot and bunion needs.
Paragon 28® is grateful for the significant contributions that Mark Myerson, MD, Jose Sanhudo, MD, and Lew Schon, MD, made in the design of this system.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.
Investor Contact:
Matt Brinckman Senior Vice President, Strategy and Investor Relations
(720) 912-1332
mbrinckman@paragon28.com
Source: Paragon 28, Inc.
FAQ
What is the Phantom® Metatarsal Shortening System?
It is a new orthopedic device by Paragon 28 for in-line shortening osteotomies of the lesser metatarsals, designed to improve treatment for metatarsalgia and floating toe.
When was the Phantom® Metatarsal Shortening System launched?
The Phantom® Metatarsal Shortening System was launched recently, as announced in the press release.
How does the Phantom® Metatarsal Shortening System improve surgical procedures?
It features a patent-pending cut guide that enhances precision during the correction of metatarsal conditions.
What impact will the Phantom® Metatarsal Shortening System have on Paragon 28's business?
The system is expected to catalyze growth in the forefoot segment and enhance the company's comprehensive portfolio of orthopedic solutions.
Who contributed to the design of the Phantom® Metatarsal Shortening System?
Notable contributions were made by surgeons Mark Myerson, Jose Sanhudo, and Lew Schon.
